1391602-17-7

Basic information

• Product Name: 2-[(2-bromo-4-nitro-phenyl)-hydrazono]-propionic acid ethyl ester
• Synonyms: 2-[(2-bromo-4-nitro-phenyl)-hydrazono]-propionic acid ethyl ester
• CAS NO: 1391602-17-7
• Molecular Weight: 330.138
• Mol File: 1391602-17-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-[(2-bromo-4-nitro-phenyl)-hydrazono]-propionic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(2-bromo-4-nitro-phenyl)-hydrazono]-propionic acid ethyl ester(1391602-17-7)
• EPA Substance Registry System: 2-[(2-bromo-4-nitro-phenyl)-hydrazono]-propionic acid ethyl ester(1391602-17-7)

Safety Data

• Hazardous Substances Data: 1391602-17-7(Hazardous Substances Data)

Upstream product

• 617-35-6 2-oxo-propionic acid ethyl ester 
• 72790-96-6 (2-bromo-4-nitro-phenyl)-hydrazine 

Downstream Products

• 1391602-18-8 2-[(4-amino-2-bromo-phenyl)-hydrazono]-propionic acid ethyl ester 
• 1391602-19-9 2-[(4-acetylamino-2-bromo-phenyl)-hydrazono]-propionic acid ethyl ester 

Relevant articles and documents

Amino-Indolyl-Substituted Imidazolyl-Pyrimidines and Their Use as Medicaments

The invention relates to new amino-indole-substituted imidazolyl-pyrimidines of formula 1 wherein R1, R2, R3, R4 and R5 are defined as in claim 1 and pharmaceutically acceptable salts thereof and the use of these compounds for the preparation of a medicament for treating a disease selected from asthma, COPD, rheumatoid arthritis, specific lymphomas and specific diseases of the nervous system.

SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted pyridinyl-pyrimidines of formula 1 wherein ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O, wherein R1, R2, R4, R3, R5 and R6 are defined as in claim 1 and wherein ring A is further optionally substituted by one or two further substituents and the pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates of the aforementioned compounds.